Table 2 Summary data for studies comparing outcomes between diagnostic biopsy and confirmatory biopsy included for this review
Author (year ) | Study characteristic a | Patient characteristic | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Study region (interval) | Study size, n | No. Upgrading, n (%) | Definition of upgrading (from bGS to pGS) | Mean age, years | Mean PSA, ng/mL | Mean PV, mL | bGS | Clinical T-stage | No. cores obtained, n | |
Anderson 2015 [32] | USA (1991–2001) | 646 | 55 (8.5) | ≤ 6 to ≥ 7 | NA | NA | NA | ≤ 6 | T1c–2a | Median 12, IQR 11–12 |
Dai 2019 [33] | USA (2005–2015) | 406 | 85 (20.9) | ≤ 6 to ≥ 7 | NA | NA | NA | ≤ 6 | T1–2 | 12 |
Herrera-Caceres 2020 [34] | Canada (2006–2018) | 726 | 159 (21.9) | ≤ 6 to ≥ 7 | NA | NA | NA | ≤ 6 | NA | Median 12, IQR 10–12 |